2-氯脱氧腺苷和放射治疗高血压的 I 期研究-猫眼课题宝

2-氯脱氧腺苷和放射治疗高血压的 I 期研究

批准号：

6290833

负责人：

JAMES MITCHELL

金额：

$0.0万

依托单位：

DIVISION OF CLINICAL SCIENCES - NCI

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/6290833

关键词：

DNA repair amination astrocytoma chlorodeoxyadenosine clinical research clinical trial phase I glioma human morbidity human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer radiation therapy neoplasm /cancer relapse /recurrence neoplastic cell neoplastic process prognosis radiation resistance radiosensitizer

项目摘要

项目成果

JAMES MITCHELL的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Radiotherapy is the most effective non-invasive treatment of high grade gliomas, however the results are far from satisfactory. The predominant mode of death following radiation is necrosis secondary to DNA damage. Although treatmnets which result in the increase in DNA damage (halogenated pyrimidines, hypoxic sensitizers) have been explored in the pre-clinical and clinical setting, inhibitors of DNA repari are a novel, untested class of agents capable of radiosensitization in vitro. 2-Chlorodeoxyadenosine (2CDA) is a potent radiosensitizer which has been shown to inhibit repair of double strand breaks in vitro. It is an adenosine analog which has demonstrated single agent activity against recurrent malignant gliomas in a phase I setting. In the present study, we are conducting a phase I dose escalation of 2CDA given during the course of accelerated hyperfractionated radiotherapy for patients with high grade glioma. - Anaplastic Astrocytoma, Glioblastoma, 2CDA, - Human Subjects

期刊论文(0)

专著(0)

科研奖励(0)

会议论文